文献速递功能神经外科

脑深部电刺激装置植入对帕金森病与特发性震颤患者体重的影响

Effects of implantation of a deep brain stimulation device on patient weight in Parkinson's disease and essential tremor.
PubMed 文献 · J Neurosurg · 2020-05-22

该回顾性研究纳入2012至2017年接受脑深部电刺激(DBS)治疗的帕金森病(PD)与特发性震颤(ET)患者,比较术前及术后3、6、12个月体重。PD患者术后体重显著增加,且丘脑底核(STN)靶点者体重与BMI增幅大于苍白球内侧部(GPi)靶点者;左旋多巴等效剂量(LED)减少与体重增加负相关;ET患者未见体重增加。

要点

  • PD患者DBS术后3、6、12个月体重均显著增加,ET患者未见体重增加。
  • STN靶点PD患者术后6、12个月体重及BMI增幅均大于GPi靶点患者。
  • PD患者LED减少与术后6、12个月体重增加呈负相关。

核心结论

  • PD患者DBS术后体重随时间显著增加,而ET患者未出现体重增加。
  • STN靶点PD患者平均体重增幅大于GPi靶点者,且术后6、12个月BMI显著高于GPi靶点者。
  • PD患者DBS术后LED减少者,术后6、12个月体重增加多于LED维持或增加者。

研究设计与样本

  • 回顾性研究,纳入2012至2017年接受DBS治疗的PD与ET患者。
  • 记录术前及术后3、6、12个月体重,比较诊断、BMI、性别、LED及UPDRS评分变化等特征。
  • 对PD患者采用分位数多变量回归分析,检验年龄及上述特征与术后体重增加的相关性。

主要发现

  • PD患者术后3个月体重平均(SE)增加2.66(0.428)kg(p<0.001)。
  • PD患者术后6个月体重平均(SE)增加3.64(0.492)kg(p<0.001)。
  • PD患者术后12个月体重平均(SE)增加4.18(0.540)kg(p<0.001)。
  • STN靶点PD患者术后6个月体重平均增加多于GPi靶点者2.558(1.020)kg(p=0.01),术后12个月多2.358(1.130)kg(p=0.04)。
  • STN靶点PD患者术后6个月BMI平均差异(SE)高于GPi靶点者2.60(1.127)kg/m2(p=0.02),术后12个月高2.36(1.112)kg/m2(p=0.04)。

临床怎么用

  • PD患者DBS术后应关注体重变化,尤其STN靶点及LED减少者。
  • ET患者DBS术后体重增加风险相对较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Deep brain stimulation (DBS) is a well-established therapy for treating neurological movement disorders. Some patients who have received DBS therapy have noticed significant weight gain. Further investigation into correlations between patient characteristics and weight gain following DBS device implantation, which the authors here have done, will provide physicians with useful clinical information. METHODS: The authors performed a retrospective study of patients with Parkinson's disease (PD) and essential tremor (ET) who had received DBS therapy in the period from 2012 to 2017. Patient weights had been recorded preoperatively and at 3, 6, and 12 months postoperatively. These data were used to compare patient characteristics, including diagnosis, body mass index (BMI), sex, levodopa equivalent dose (LED), and change in Unified Parkinson's Disease Rating Scale (UPDRS) score. For PD patients, a quantile multivariate regression analysis was used to examine whether significant correlations existed between several of these patient characteristics, as well as age and weight gain following implantation. RESULTS: PD patients had gained a significant amount of weight at 3 months (mean [SE] 2.66 [0.428] kg, p < 0.001), 6 months (3.64 [0.492] kg, p < 0.001), and 12 months (4.18 [0.540] kg, p < 0.001) after DBS placement. Patients who had undergone subthalamic nucleus (STN) DBS device placement gained, on average, more weight than the patients with globus pallidus internus (GPi) placement at both 6 months (mean 2.558 [1.020] kg, p = 0.01) and 12 months (2.358 [1.130] kg, p = 0.04). BMI in the STN cohort was greater than that in the GPi cohort at 6 months (mean difference [SE] 2.60 [1.127] kg/m2, p = 0.02) and at 12 months (2.36 [1.112] kg/m2, p = 0.04). A reduction in LED was negatively correlated with weight change at 6 months (r = -0.33, p < 0.001) and 12 months (r = -0.41, p < 0.001). There was no weight gain correlated with DBS therapy for ET. CONCLUSIONS: PD patients experienced a significant change in weight over time after DBS therapy, whereas ET patients did not. PD patients with an STN target site experienced greater weight gain, on average, than those with a GPi target site. Furthermore, there was a significant increase in BMI at 6 and 12 months in patients with an STN target compared to that in patients with a GPi target. PD patients whose LED was reduced after DBS gained more weight at 6 and 12 months after surgery than the patients whose LED was kept at the same level or increased.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Monteferrante NR, Wilhelmi BG, Lambert M, et al. Effects of implantation of a deep brain stimulation device on patient weight in Parkinson's disease and essential tremor. J Neurosurg. 2020. PMID: 32442969. doi:10.3171/2020.2.JNS192354

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。